← Leaderboards
Peter Anderson
University Of Colorado Denver
$575,535
Attributed
$575,535
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $438.7K · FY2006–08$500K$375K$250K$125K$0
'06
'07
'08
Funding mix
By agency
NIH$575,535 · 5
By mechanism
M01$575,535 · 5
Top collaborators
No co-investigators on record.
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Andrew S Kraft$21,224,247
- Ronald J Sokol$193,385,254
- Dedra S Buchwald$63,799,088
- V Michael Holers$38,234,826
- Spero M Manson$45,709,705
Research focus
Computer Retrieval Of Information On Scientific Projects DatabaseAnti-Retroviral AgentsToxic EffectUnited States National Institutes Of HealthInstitutionGrantPharmaceutical PreparationsSourceBaseFundingResourcesResearch PersonnelDesignCytochrome P-450 Cyp3a5 (Human)Cytochrome P450 3aFutureCyp3a4 GeneCellsDrug ToxicityConceptDrug KineticsDrug ExposureAtazanavirDrug Efficacy
Grant awards (5)
GENETIC-DETERMINANTS OF PROTEASE INHIBITOR PHARMACOLOGY$56,325
M01 · FY2008 · RR · contact PI
SEX- AND DISEASE-DEPENDENT NUCLEOSIDE ANALOG TOXICITY$30,235
M01 · FY2008 · RR · contact PI
GENETIC-DETERMINANTS OF PROTEASE INHIBITOR PHARMACOLOGY$285,468
M01 · FY2007 · RR · contact PI
SEX- AND DISEASE-DEPENDENT NUCLEOSIDE ANALOG TOXICITY$153,237
M01 · FY2007 · RR · contact PI
SEX- AND DISEASE-DEPENDENT NUCLEOSIDE ANALOG TOXICITY$50,270
M01 · FY2006 · RR · contact PI